英国风湿病学会生物制剂登记册。
The British Society for Rheumatology biologics register.
作者信息
Watson K, Symmons D, Griffiths I, Silman A
机构信息
Epidemiology Research Unit, Manchester University Medical School, Manchester, UK.
出版信息
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv42-3. doi: 10.1136/ard.2005.042499.
Abstract
The British Society for Rheumatology (BSR) established a nationwide register for patients with rheumatological disorders treated with biologic agents. The register is designed as a national prospective study whose primary purpose is to assess long term toxicity from the use of these agents in routine practice. In addition, the data will be capable of addressing the benefits from their use in relation to their toxicity. One specific feature of the BSR register is the recruitment and collection of data from a parallel comparison group, comprising patients with active rheumatoid arthritis treated with conventional disease modifying agents. Both class specific and drug specific analyses of the group treated with biologicals are planned.
摘要
英国风湿病学会（BSR）建立了一个全国性的生物制剂治疗风湿病患者登记册。该登记册被设计为一项全国性前瞻性研究，其主要目的是评估在常规临床实践中使用这些药物的长期毒性。此外，这些数据将能够说明使用这些药物的益处及其毒性。BSR登记册的一个特点是从一个平行对照组招募和收集数据，该对照组由接受传统病情缓解药物治疗的活动性类风湿关节炎患者组成。计划对接受生物制剂治疗的组进行类别特异性和药物特异性分析。
相似文献
1
The British Society for Rheumatology biologics register.英国风湿病学会生物制剂登记册。
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv42-3. doi: 10.1136/ard.2005.042499.
2
British Society for Rheumatology Biologics Register.英国风湿病学会生物制剂注册库
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii28-9. doi: 10.1136/ard.62.suppl_2.ii28.
3
Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries.发布风湿病纵向观察性药物研究报告清单：基于生物制剂登记处经验的EULAR对STROBE指南的扩展
Ann Rheum Dis. 2014 Mar;73(3):628. doi: 10.1136/annrheumdis-2013-204102. Epub 2013 Sep 20.
4
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology.EULAR 关于在风湿病中建立、分析和报告生物制剂注册安全性数据时应考虑的要点。
Ann Rheum Dis. 2010 Sep;69(9):1596-602. doi: 10.1136/ard.2009.125526. Epub 2010 Jun 4.
5
Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.生物制剂治疗的类风湿关节炎患者的严重感染：来自英国风湿病学会生物制剂登记处类风湿关节炎的结果。
Ann Rheum Dis. 2018 Jun;77(6):905-910. doi: 10.1136/annrheumdis-2017-212825. Epub 2018 Mar 28.
6
7
Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.药物疗法过多与治疗反应和严重不良事件有关：英国风湿病学会生物制剂治疗类风湿关节炎注册研究的结果。
Rheumatology (Oxford). 2019 Oct 1;58(10):1767-1776. doi: 10.1093/rheumatology/kez037.
8
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.抗肿瘤坏死因子治疗对曾患有恶性肿瘤的类风湿关节炎患者癌症发病率的影响：来自英国风湿病学会生物制剂登记处的结果。
Arthritis Care Res (Hoboken). 2010 Jun;62(6):755-63. doi: 10.1002/acr.20129.
9
BSR Biologics Registry.英国风湿病学会生物制剂注册库
Rheumatology (Oxford). 2004 Dec;43(12):1463-4. doi: 10.1093/rheumatology/keh356. Epub 2004 Aug 24.
10
The Corrona US registry of rheumatic and autoimmune diseases.美国科罗纳风湿性和自身免疫性疾病登记处。
Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S96-S99. Epub 2016 Oct 19.
引用本文的文献
1
The pattern of anti-IL-6 versus non-anti-IL-6 biologic disease modifying anti-rheumatic drugs use in patients with rheumatoid arthritis in Wales, UK: a real-world study using electronic health records.英国威尔士类风湿关节炎患者中抗白细胞介素-6与非抗白细胞介素-6生物改善病情抗风湿药物的使用模式：一项利用电子健康记录的真实世界研究
Rheumatol Adv Pract. 2024 Dec 14;9(1):rkae140. doi: 10.1093/rap/rkae140. eCollection 2025.
2
Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA.类风湿关节炎患者体重与托珠单抗疗效之间的关联：英国风湿病学会类风湿关节炎生物制剂注册研究（BSRBR-RA）的结果
Rheumatology (Oxford). 2025 Feb 1;64(2):477-483. doi: 10.1093/rheumatology/keae500.
3
Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?评估生物制剂治疗期间严重感染（包括结核分枝杆菌）：治疗线是否重要？
Rheumatology (Oxford). 2024 Jul 1;63(7):1957-1964. doi: 10.1093/rheumatology/kead515.
4
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.生物制剂和靶向合成改善病情抗风湿药物在类风湿关节炎临床应用中的安全性：来自 ARTIS 研究计划的结果。
Ann Rheum Dis. 2023 May;82(5):601-610. doi: 10.1136/ard-2022-223762. Epub 2023 Feb 14.
5
Lebanese Hospital-Based Rheumatoid Arthritis Registry: Characteristics of Patients and Comparison with Other Populations.黎巴嫩医院类风湿关节炎登记处：患者特征及与其他人群的比较。
Mediterr J Rheumatol. 2022 Jun 30;33(2):218-223. doi: 10.31138/mjr.33.2.218. eCollection 2022 Jun.
6
Implementing an automated monitoring process in a digital, longitudinal observational cohort study.在数字化纵向观察队列研究中实施自动化监测流程。
Arthritis Res Ther. 2021 Jul 7;23(1):181. doi: 10.1186/s13075-021-02563-2.
7
Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis.在英国风湿病学会生物制剂注册处类风湿关节炎患者中，抗 TNF-α 治疗起始后脱髓鞘事件。
Neurol Neuroimmunol Neuroinflamm. 2021 Apr 16;8(3). doi: 10.1212/NXI.0000000000000992. Print 2021 May.
8
Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.背景甲氨蝶呤在延长老年类风湿关节炎患者 TNF 抑制剂药物存活期中是否具有优势？英国风湿病学会生物制剂登记处的分析。
Rheumatology (Oxford). 2020 Sep 1;59(9):2563-2571. doi: 10.1093/rheumatology/kez671.
9
Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA.早期对抗 TNF 反应预测长期结局，包括持续缓解：BSRBR-RA 的分析。
Rheumatology (Oxford). 2020 Jul 1;59(7):1709-1714. doi: 10.1093/rheumatology/kez518.
10
Thoracic Manifestations of Rheumatoid Arthritis.类风湿关节炎的胸部表现。
Clin Chest Med. 2019 Sep;40(3):545-560. doi: 10.1016/j.ccm.2019.05.003. Epub 2019 Jul 6.
本文引用的文献
1
Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.类风湿关节炎中的淋巴瘤：甲氨蝶呤和抗肿瘤坏死因子治疗对18572例患者的影响。
Arthritis Rheum. 2004 Jun;50(6):1740-51. doi: 10.1002/art.20311.
2
Rheumatoid arthritis and malignant lymphomas.类风湿关节炎与恶性淋巴瘤。
Curr Opin Rheumatol. 2004 May;16(3):254-61. doi: 10.1097/00002281-200405000-00014.
3
Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives.类风湿性关节炎患者及其一级亲属患恶性淋巴瘤的风险。
Arthritis Rheum. 2003 Apr;48(4):963-70. doi: 10.1002/art.10939.
4
Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.肿瘤坏死因子拮抗剂治疗与淋巴瘤的发生：向美国食品药品监督管理局报告的26例病例
Arthritis Rheum. 2002 Dec;46(12):3151-8. doi: 10.1002/art.10679.
5
Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.类风湿关节炎患者的疾病活动度与淋巴瘤风险：巢式病例对照研究。
BMJ. 1998 Jul 18;317(7152):180-1. doi: 10.1136/bmj.317.7152.180.
Zotero 插件